Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds.

Chumanevich AA, Chaparala A, Witalison EE, Tashkandi H, Hofseth AB, Lane C, Pena E, Liu P, Pittman DL, Nagarkatti P, Nagarkatti M, Hofseth LJ, Chumanevich AA.

Oncotarget. 2017 Jan 3;8(1):228-237. doi: 10.18632/oncotarget.13894.


Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties.

Chumanevich AA, Witalison EE, Chaparala A, Chumanevich A, Nagarkatti P, Nagarkatti M, Hofseth LJ.

Oncotarget. 2016 Aug 16;7(33):52928-52939. doi: 10.18632/oncotarget.10608.


Molecular targeting of protein arginine deiminases to suppress colitis and prevent colon cancer.

Witalison EE, Cui X, Causey CP, Thompson PR, Hofseth LJ.

Oncotarget. 2015 Nov 3;6(34):36053-62. doi: 10.18632/oncotarget.5937.


Inhibiting protein arginine deiminases has antioxidant consequences.

Witalison EE, Cui X, Hofseth AB, Subramanian V, Causey CP, Thompson PR, Hofseth LJ.

J Pharmacol Exp Ther. 2015 Apr;353(1):64-70. doi: 10.1124/jpet.115.222745. Epub 2015 Jan 29.


The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest.

Cui X, Witalison EE, Chumanevich AP, Chumanevich AA, Poudyal D, Subramanian V, Schetter AJ, Harris CC, Thompson PR, Hofseth LJ.

PLoS One. 2013;8(1):e53791. doi: 10.1371/journal.pone.0053791. Epub 2013 Jan 7.

Supplemental Content

Loading ...
Support Center